StreetInsider.com News Articles

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events:

Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.

TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (virtual) – fireside chat on Wednesday, September 23, 2026, at 1:30-1:55 pm ET.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.

TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (virtual) – fireside chat on Wednesday, September 23, 2026, at 1:30-1:55 pm ET.

Form 4 Rapport Therapeutics, For: Aug 25 Filed by: Ceesay Abraham

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981550.html

Form 4 Rapport Therapeutics, For: Aug 25 Filed by: Ceesay Abraham

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981550.html

Form 4 Rapport Therapeutics, For: Aug 24 Filed by: Yeleswaram Krishnaswamy

Wed, 26 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26981380.html

Form 4 Rapport Therapeutics, For: Aug 24 Filed by: Yeleswaram Krishnaswamy

Wed, 26 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260826/26981380.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Tue, 25 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26975110.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Tue, 25 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26975110.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Mon, 24 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260824/26968448.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Mon, 24 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260824/26968448.html

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Mon, 24 Aug 2026 07:00:00 -0400

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here.

The event will feature leading experts in bipolar disorder Mauricio Tohen, MD, DrPH, MBA (University of New Mexico Health Science Center), and Gary Sachs,

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Mon, 24 Aug 2026 07:00:00 -0400

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here.

The event will feature leading experts in bipolar disorder Mauricio Tohen, MD, DrPH, MBA (University of New Mexico Health Science Center), and Gary Sachs,

Form 4 Rapport Therapeutics, For: Aug 19 Filed by: Yeleswaram Krishnaswamy

Thu, 20 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260820/26956240.html

Form 4 Rapport Therapeutics, For: Aug 19 Filed by: Yeleswaram Krishnaswamy

Thu, 20 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260820/26956240.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Wed, 19 Aug 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260819/26950627.html

Form 144 Rapport Therapeutics, Filed by: Yeleswaram Krishnaswamy

Wed, 19 Aug 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260819/26950627.html

Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James

Mon, 17 Aug 2026 06:16:19 -0400

Raymond James analyst Tiago Fauth raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $75.00 (from $68.00) while maintaining a Strong Buy rating.
The analyst comments "We believe RAP-219’s bipolar mania readout is one of the most asymmetric catalysts in SMID biotech. RAPP is up 56% YTD (vs. XBI up 29%), but we believe this move had little to do with the bipolar program, as the move from ~$1B to ~$2B EV is the exact same pattern we saw with XENE following their Ph2 FOS data. We think XENE ($62.35/Not Covered) sets a highly relevant precedent and offers insights into

Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James

Mon, 17 Aug 2026 06:16:19 -0400

Raymond James analyst Tiago Fauth raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $75.00 (from $68.00) while maintaining a Strong Buy rating.
The analyst comments "We believe RAP-219’s bipolar mania readout is one of the most asymmetric catalysts in SMID biotech. RAPP is up 56% YTD (vs. XBI up 29%), but we believe this move had little to do with the bipolar program, as the move from ~$1B to ~$2B EV is the exact same pattern we saw with XENE following their Ph2 FOS data. We think XENE ($62.35/Not Covered) sets a highly relevant precedent and offers insights into

Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Third Rock Ventures V, L.P.

Fri, 14 Aug 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260814/26930848.html

Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Third Rock Ventures V, L.P.

Fri, 14 Aug 2026 16:20:00 -0400
si-local-file:///var/storage/secattach/20260814/26930848.html

Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:05:00 -0400
si-local-file:///var/storage/secattach/20260814/26928763.html

Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:05:00 -0400
si-local-file:///var/storage/secattach/20260814/26928763.html

Rapport Therapeutics (RAPP) PT Raised to $66 at H.C. Wainwright

Thu, 13 Aug 2026 06:55:16 -0400
H.C. Wainwright analyst Douglas Tsao raised the price target on Rapport Therapeutics (NASDAQ: RAPP) to $66.00 (from $40.00) while maintaining a Buy rating.

Form 4 Rapport Therapeutics, For: Aug 10 Filed by: Ceesay Abraham

Wed, 12 Aug 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260812/26913590.html

Form 4 Rapport Therapeutics, For: Aug 10 Filed by: Ceesay Abraham

Wed, 12 Aug 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260812/26913590.html